To the Editor:

THE coronavirus disease 2019 (COVID-19) pandemic has devastated the world. About 15% of infected patients need intensive care.[@bib0001] A small proportion of these patients could benefit from extracorporeal membrane oxygenation (ECMO).[@bib0002] Performing a tracheostomy on these patients is considered to be a high-risk aerosol-generating procedure, with implications for staff safety.[@bib0003] Guidelines to mitigate the risks associated with tracheostomy in COVID patients[@bib0004] have not reported actual experience but delay of the procedure.[@bib0005] The risk of bleeding also is greater in patients on ECMO who require tracheostomy.[@bib0006] Nevertheless, tracheostomy can facilitate tracheal toilet, reduce sedative requirements, and decrease the duration of mechanical ventilation.

Case Series {#sec0001}
===========

At the start of the COVID-19 surge, we established a prospective tracheostomy database. In addition, we modified the procedure to reduce risk of aerosol spread to staff, as described in the following: (1) all procedures are performed in the patient\'s own intensive care unit (ICU) isolation room; (2) minimization of staff present (operator, bronchoscopist, nurse) and minimization of the number of operators as recommended by Tay et al.[@bib0007]; (3) use of disposable bronchoscopy equipment on a single trolley; and (4) discontinuation of mechanical ventilation during tracheostomy.

We performed 38 percutaneous tracheostomies in mechanically ventilated patients on ECMO during 8 weeks of the COVID-19 pandemic in our institution (March 27-May 15, 2020) ([Table 1](#tbl0001){ref-type="table"} ). We are 1 of the 5 designated ECMO centers in the United Kingdom and admitted more than 40 patients supported with ECMO during the COVID-19 pandemic. The decision to perform tracheostomy was made by the duty day intensivist. The average time of tracheal intubation before tracheostomy was 11.66 days. All procedures were successful.Table 1Clinical Characteristics of COVID ECMO Tracheostomy Patients.Table 1DemographicsAgeMeanSD45.509.59SexNumberPercent Male3181.58% Female718.42%BMIMeanSD28.2111.30ComorbidityNumberPercent None1128.95% Asthma718.42% Diabetes mellitus923.68% Hypertension923.68% Obesity1334.21% Obstructive sleep apnea25.26% Current smoker25.26% Hypothyroidism37.89% Encephalitis12.63% Postpartum12.63% Sickle cell trait12.63% Sarcoidosis12.63%Duration of intubation before tracheostomyMeanSD11.664.63Duration to cessation of invasive mechanical ventilationMeanSD Still ventilated25 Successful (tracheostomy mask/speaking valve)1318.8511.42Duration to decannulation/length of stayMeanSD Ongoing care27 Successful618.005.87 Repatriated with tracheostomy524.7510.61Outcome/length of stayMeanSD Discharged to ward/repatriated1023.508.12 Ongoing care in the hospital2232.8710.41 Deceased619.449.29Cause of death Intracranial hemorrhage2 Multiorgan failure4ComplicationsNumberPercent Bleeding from skin2Both had anticoagulant stopped for the procedure Both needed a purse string sutureAnticoagulant stopped perioperativelyNumberPercent Yes2360.53% No1539.47%[^1]

Complications and Safety {#sec0002}
------------------------

Complications were minimal. No immediate complications, such as pneumothorax or tracheostomy malposition, were observed. No transfusion of blood products was required for tracheostomy bleeding, but 2 patients needed additional skin sutures to stop skin bleeding. We asked medical staff to report any sickness after the procedure, and to date there have been no reports of sickness or sick leave among medical staff relating to the tracheostomies.

Procedure {#sec0003a}
---------

The percutaneous dilatational method was used for all tracheostomies, which were performed at the bedside in an ICU with isolation rooms. A preprepared trolley with all equipment necessary for the surgery was prepared in a sterile area outside the ICU ([Fig 1](#fig0001){ref-type="fig"} ). Family consent was obtained, the World Health Organization safe surgical checklist procedure was followed, and rescue airway equipment was placed outside the room before commencement of the procedures. Full personal protective equipment included an FFP3 facemask, visor, gown, and gloves for the tracheostomy team and bedside nurse.Fig 1Preprepared tracheostomy and fiberoptic bronchoscopy trolley.Fig 1

In all patients, anesthesia was maintained with a propofol infusion, 1% at 4 mg/kg/h, which already was running usually at a lower rate. Muscle relaxation was achieved by a single dose of atracurium, 50 mg, or rocuronium, 50 mg. Local anesthesia with 10 mL of 1% lidocaine with 1:200000 epinephrine was used for skin, subcutaneous tissues, and tracheal mucosa. A disposable Ambu bronchoscope (Ambu, Ballerup, Denmark) was used in all patients. Ventilation was discontinued during withdrawal of the endotracheal tube, dilator exchange, and tracheostomy tube insertion. Ventilation then was resumed, and position was confirmed bronchoscopically and via capnography. All tracheostomies were performed using TRACOE twist kit sizes 7- to- 10 (TRACOE Medical GmbH, Nieder-Olm, Germany). Skin incision with a scalpel was avoided if possible. More than half of the tracheostomies were performed by the same duo of operator and bronchoscopist.

In our previously published experience in the *Journal of Cardiothoracic and Vascular Anesthesia*, we described stopping heparin infusions routinely 2- to- 4 hours before tracheostomy to prevent bleeding in ECMO patients. However, we found that COVID-19 patients are in a hypercoagulable state[@bib0008] and that anticoagulation does not need to be stopped routinely. The Activated Prothrombin Time (APTT) ratio of 1.5- to- 1.8 was deemed safe for the procedure. One patient was receiving argatroban because of heparin-induced thrombotic thrombocytopenia, and this was not discontinued. As our experience grew, anticoagulation was not discontinued in 15 patients, without bleeding complications.

Perspective {#sec0004}
===========

Tracheostomy remains a valuable procedure for mechanically ventilated patients. ECMO support allows for the discontinuation of mechanical ventilation for a short period without further worsening of hypoxia and therefore reduction of risk of aerosolization. We found that continuing anticoagulation during dilatational percutaneous tracheostomy for ECMO-supported COVID-19 patients did not lead to bleeding complications. Limiting the number of operators allows for concentration of expertise.
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[^1]: Abbreviations: BMI, body mass index; COVID, coronavirus disease; ECMO, extracorporeal membrane oxygenation; SD, standard deviation.
